Literature DB >> 3350996

Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels.

J H Meador-Woodruff1, M Akil, R Wisner-Carlson, L Grunhaus.   

Abstract

Tricyclic antidepressants (TCAs) have been occasionally reported to cause delirium, probably via a central antimuscarinic action. Nine of 16 patients with plasma TCA levels greater than 450 ng/ml developed cognitive or behavioral toxicity, compared with only one of 15 patients in a control group with plasma TCA levels between 150 and 450 ng/ml. The clinician should be aware of this potential adverse effect of TCA therapy, which may be easily preventable through the combination of careful clinical monitoring and liberal use of plasma TCA levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350996

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.

Authors:  Sven Ulrich; Jürgen Läuter
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 4.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

5.  Memory Impairment following Acute Tricyclic Antidepressants Overdose.

Authors:  Nastaran Eizadi-Mood; Shahla Akouchekian; Ahmad Yaraghi; Mehrnazsadat Hakamian; Rasool Soltani; Ali Mohammad Sabzghabaee
Journal:  Depress Res Treat       Date:  2015-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.